Cardiotoxicity Screening

• hERG Predictor fluorescence polarisation assay (Invitrogen)

Cardiotoxicity is one of the main reasons for safety-related compound attrition and drug withdrawals, and therefore should be screened in the early stages of drug discovery. We offer a cost-efficient and rapid screening tool for evaluating cardiotoxicity as a part of our toxicity screening portfolio. Full electrophysiological cardiac safety panel is available via a partner. 

Our rapid hERG Predictor fluorescence polarisation assay is used for screening of compounds acting as potential ligands or blockers of hERG channel. The assay utilises 384-well plate format and delivers IC₅₀ values towards hERG blockage in relation to a well-known hERG ligand, E-4031 as well as negative control.